TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03830476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance- and Commitment therapy group for parents to children with disabilities
Description: ACT groups adjusted for parents of children with (any kind of) disabilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual.
Description: Treatment as usual within outpatient disability services.
Study: NCT01766063

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY 86-5046)
Description: Patients will be followed-up for 24 months
Study: NCT05103579

Intervention type: DEVICE
Intervention: MindMics
Description: Patients rhythms was recorded using MindMics device

Intervention type: DEVICE
Intervention: MindMics
Description: Patients rhythms was recorded using MindMics device
Study: NCT02481648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT01824654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Validation of the new rigid registration software
Description: Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Validation of the new elastic registration software
Description: This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
Study: NCT01009437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Tissue collection is from all patients, including the control, phase I and phase II patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Tissue collection is from all patients, including the control, phase I and phase II patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Tissue collection is from all patients, including the control, phase I and phase II patients.
Study: NCT04606199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention, up to 5 minutes 0-3 times/day
Description: The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
Study: NCT02196883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection
Study: NCT03596047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial wave therapy
Description: 6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapy
Description: There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
Study: NCT03727646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: nicotinamide riboside supplied as 250mg capsules
Study: NCT05935878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Oxford Unicompartmental Knee Arthroplasty
Description: All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Oxford Unicompartmental Knee Arthroplasty
Description: All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
Study: NCT04920370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1720 SC
Description: ALXN1720 will be administered via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1720 SC
Description: ALXN1720 will be administered via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1720 SC
Description: ALXN1720 will be administered via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1720 IV
Description: ALXN1720 will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered via SC route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo will be administered via SC route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo will be administered via IV route.
Study: NCT02066870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved.
Study: NCT01247740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuTRIflex Lipid peri
Description: parenteral nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: compounded monobag
Description: parenteral nutrition
Study: NCT02908555

Intervention type: OTHER
Intervention: No intervention
Description: This is a descriptive study with no intervention
Study: NCT00399776

Intervention type: RADIATION
Intervention: Bone Density Test
Description: Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents

Intervention type: RADIATION
Intervention: Bone Density Test
Description: Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
Study: NCT00637481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00980213

Intervention type: DRUG
Intervention: sunitinib
Description: sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
Study: NCT02138994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science Wound Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple Antibiotic Ointment Neosporin
Description: Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months
Study: NCT02108574

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Filter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhinix Nasal Filter
Study: NCT02897206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: A wide-spectre antibiotic from the carbapenem group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An imipenem-matching placebo
Study: NCT01801800

Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
Study: NCT01458600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: T Diclofenac 50 mg twice daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: T Methimazole 5 mg 3x2 for 18 months

Intervention type: DRUG
Group type: OTHER
Intervention: Methimazole
Description: T Methimazole 5 mg 3x2 for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-thyroxin
Description: L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months

Intervention type: DRUG
Group type: OTHER
Intervention: L-thyroxin
Description: L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics

Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol
Description: T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics

Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol
Description: T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
Study: NCT00532116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 6mg
Description: STS 6mg/24hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 12mg
Description: EMSAm 12mg/24Hr
Study: NCT01507506

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA\> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.
Study: NCT03908606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Supra and subgingival scaling and root planing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Supra and subgingival scaling and root planing.
Study: NCT01439906

Intervention type: PROCEDURE
Intervention: Surgical correction of the deformity
Description: Three different surgical techniques are used:~* lumbar fusion vs thoraco-lumbar fusion~* iliac fixation vs fixation to the sacrum~* posterior + interbody fusion vs posterior interbody fusion
Study: NCT02861820

Intervention type: DEVICE
Intervention: MRI: Brain Imaging Data Collection
Description: This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
Study: NCT02150798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat and low carbohydrate diet
Description: high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control diet. At baseline and at 2 month of following, the variables that were evaluated,
Study: NCT04320446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test in the morning
Description: The exercise test was performed between 8 a.m and 11 a.m

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Test in the morning
Description: The exercise test was performed between 8 a.m and 11 a.m

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test in the afternoon
Description: The exercise test was performed between 5 p.m. and 8 p.m.a

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Test in the afternoon
Description: The exercise test was performed between 5 p.m. and 8 p.m.a
Study: NCT03729960

Intervention type: OTHER
Group type: OTHER
Intervention: LENA recorder
Description: The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
Study: NCT02212392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
Study: NCT02838303

Intervention type: OTHER
Group type: OTHER
Intervention: Organophosphate
Description: Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous

Intervention type: OTHER
Group type: OTHER
Intervention: Organophosphate
Description: Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Multineem, WHO Class U: Unlikely to present acute hazard in normal use

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Multineem, WHO Class U: Unlikely to present acute hazard in normal use
Study: NCT04207970

Intervention type: OTHER
Intervention: Adapted Structured Clinical Management
Description: Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
Study: NCT04478955

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer test
Description: Tear tests Meibomian gland grading test

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer test
Description: Tear tests Meibomian gland grading test

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer test
Description: Tear tests Meibomian gland grading test

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer test
Description: Tear tests Meibomian gland grading test
Study: NCT01101932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515 Tablet
Description: Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
Study: NCT04648072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: As previously described.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor Canal Block
Description: As previously described.
Study: NCT00985491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobarrier Liner
Description: Medical device placed endoscopically in the duodenum
Study: NCT02790515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)
Description: Given intravenous (IV) prior to transplant on Days -14, -13, -12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
Study: NCT04648072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular Injection
Description: As previously described.
Study: NCT02790515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV infusion prior to transplant on Day -9.
Study: NCT04648072

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periarticular Injection
Description: As previously described.
Study: NCT02468323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive regular spinal anesthesia
Study: NCT02790515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV prior to transplant on Days -8, -7, -6, -5, and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV prior to transplant on Days -2 and -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
Study: NCT03566771

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLOSS
Description: Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
Study: NCT02150551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stromal cells
Description: This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :\> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : \>34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
Study: NCT04413656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ablation
Description: Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).